Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
472.57
-9.43 (-1.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,288,902
Open
482.32
Bid (Size)
469.31 (80)
Ask (Size)
476.00 (240)
Prev. Close
482.00
Today's Range
471.58 - 483.66
52wk Range
362.50 - 533.67
Shares Outstanding
259,428,394
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
July 21, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation
↗
July 21, 2026
Via
Chartmill
Performance
YTD
+4.5%
+4.5%
1 Month
+1.2%
+1.2%
3 Month
+8.2%
+8.2%
6 Month
+6.9%
+6.9%
1 Year
+3.1%
+3.1%
More News
Read More
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
↗
July 19, 2026
Via
The Motley Fool
Topics
Intellectual Property
1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question
July 16, 2026
Via
StockStory
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
↗
July 15, 2026
Via
Benzinga
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
↗
July 14, 2026
Via
The Motley Fool
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
↗
July 13, 2026
Via
The Motley Fool
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
↗
July 11, 2026
Via
MarketBeat
Is This Biotech Stock a Buy Near Its 52-Week High?
↗
July 10, 2026
Via
The Motley Fool
Why This Pharmaceutical Stock Jumped Close to 100% This Week
↗
July 10, 2026
Via
The Motley Fool
Topics
Bonds
3 Reasons to Buy CRISPR Therapeutics Stock
↗
July 10, 2026
Via
The Motley Fool
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
↗
July 10, 2026
Via
The Motley Fool
Topics
Intellectual Property
1 Momentum Stock to Research Further and 2 Facing Headwinds
July 09, 2026
Via
StockStory
Vertex’s Crinetics Deal Balances Growth with Integration Risk
↗
July 08, 2026
Via
MarketBeat
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
↗
July 08, 2026
Via
The Motley Fool
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
↗
July 08, 2026
Via
The Motley Fool
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
↗
July 07, 2026
Via
The Motley Fool
Topics
Intellectual Property
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
July 07, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 Cash-Heavy Stocks with Promising Prospects
July 07, 2026
Via
StockStory
Which S&P500 stocks are showing activity after the closing bell on Monday?
↗
July 06, 2026
Via
Chartmill
Vertex to Acquire Crinetics Pharmaceuticals
July 06, 2026
From
Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
Via
Business Wire
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher?
↗
July 06, 2026
Via
The Motley Fool
While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead
↗
July 05, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
↗
July 03, 2026
Via
The Motley Fool
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
July 01, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Frequently Asked Questions
Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 472.57
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 07/22/26 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 122.60B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 123B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.